Kim Huynh-Ba
Research Subjects
Research Interests
Kim Huynh-Ba has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Gary Buehler
Center for Drug Evaluation and Research, Office of Generic Drugs
2 shared publications - Abdel Aziz Saleh
Eastern Mediterranean Regional Office
1 shared publication Ajay Acharya
Merck & Co., Inc., Kenilworth, USA
1 shared publicationAlexandra Beumer Sassi
Voisin Consulting Life Sciences, Cambridge, MA, USA
1 shared publication- Alvin J. Melveger
AJM Technical Consulting
1 shared publication Andrea Schirmer
Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, USA
1 shared publication
Latest Publications
- Open Access
- 1 May 2023
- Published by Springer Nature in AAPS Open
- Vol. 9 (1) , 1-14
Stability considerations for drug-device combination products-21 CFR part 4 update
Combination products are therapeutic and diagnostic products that include two or more of the following: drug, biologic, and device. These products are needed for enhanced clinical outcomes and have more than one Mode of Action (MOA). Therefore, they require a more complex regulatory pathway and compliance with a minimum of two (2) sets of regulatory standards. In 2013, the 21 Code of Federal Regulations (CFR) Part 4 was published to clarify the applicable GMP regulations when drugs, devices, or biological products are included. The FDA (U.S. Food and Drug Administration) released additional guidance in 2017 to streamline the regulatory framework and provide transparency about demonstrating GMP compliance when multiple regulatory standards overlap. This paper summarizes the Current Good Manufacturing Practice (CGMP) requirements for drug-device combination products (Biologic combinations are not discussed in this paper). Emphasis is placed on considerations for structuring a compliant drug-device stability program, including the use of bracketing and matrixing the test schedule to support the establishment of the product expiry date and how legacy products can be evaluated to meet current standards.
- 1 May 2023
- Published by Springer Nature in AAPS Open
- Vol. 9 (1) , 1-14
Open AccessStability considerations for drug-device combination products-21 CFR part 4 update
Combination products are therapeutic and diagnostic products that include two or more of the following: drug, biologic, and device. These products are needed for enhanced clinical outcomes and have more than one Mode of Action (MOA). Therefore, they require a more complex regulatory pathway and compliance with a minimum of two (2) sets of regulatory standards. In 2013, the 21 Code of Federal Regulations (CFR) Part 4 was published to clarify the applicable GMP regulations when drugs, devices, or biological products are included. The FDA (U.S. Food and Drug Administration) released additional guidance in 2017 to streamline the regulatory framework and provide transparency about demonstrating GMP compliance when multiple regulatory standards overlap. This paper summarizes the Current Good Manufacturing Practice (CGMP) requirements for drug-device combination products (Biologic combinations are not discussed in this paper). Emphasis is placed on considerations for structuring a compliant drug-device stability program, including the use of bracketing and matrixing the test schedule to support the establishment of the product expiry date and how legacy products can be evaluated to meet current standards.
- Open Access
- 5 December 2022
- Published by Springer Nature in AAPS Open
- Vol. 8 (1) , 1-9
Meeting report: Advancing accelerated regulatory review with Real-Time Oncology Review (RTOR), Project Orbis, and the Product Quality Assessment Aid
The American Association of Pharmaceutical Scientists (AAPS) Chemistry, Manufacturing, and Controls (CMC) Community hosted two virtual panel discussions focusing on several novel regulatory review pathways for innovative oncology products: Real-Time Oncology Review (RTOR), Project Orbis, and the Product Quality Assessment Aid (PQAAid). The panel sessions were held on August 27, 2021, for the discussion of RTOR, and January 21, 2022, for the discussion of Project Orbis and the PQAAid. Both panel sessions included representatives from the US Food and Drug Administration (FDA) and subject matter experts from the pharmaceutical and biotechnology industries, with the aim of facilitating knowledge sharing on CMC-specific advantages, challenges, eligibility criteria for participation, and operational modifications instituted through the utilization of these acceleration initiatives. Key topics included managing cross-regional regulatory CMC requirements, adapting to expedited development timelines, coordinating interactions between health authorities and industry, and potential opportunities for future improvement and expansion of these programs. As RTOR, Project Orbis, and PQAAid are relatively new initiatives, the experiences shared by the panel experts are valuable for providing deeper insight into these new regulatory pathways and processes.
- 5 December 2022
- Published by Springer Nature in AAPS Open
- Vol. 8 (1) , 1-9
Open AccessMeeting report: Advancing accelerated regulatory review with Real-Time Oncology Review (RTOR), Project Orbis, and the Product Quality Assessment Aid
The American Association of Pharmaceutical Scientists (AAPS) Chemistry, Manufacturing, and Controls (CMC) Community hosted two virtual panel discussions focusing on several novel regulatory review pathways for innovative oncology products: Real-Time Oncology Review (RTOR), Project Orbis, and the Product Quality Assessment Aid (PQAAid). The panel sessions were held on August 27, 2021, for the discussion of RTOR, and January 21, 2022, for the discussion of Project Orbis and the PQAAid. Both panel sessions included representatives from the US Food and Drug Administration (FDA) and subject matter experts from the pharmaceutical and biotechnology industries, with the aim of facilitating knowledge sharing on CMC-specific advantages, challenges, eligibility criteria for participation, and operational modifications instituted through the utilization of these acceleration initiatives. Key topics included managing cross-regional regulatory CMC requirements, adapting to expedited development timelines, coordinating interactions between health authorities and industry, and potential opportunities for future improvement and expansion of these programs. As RTOR, Project Orbis, and PQAAid are relatively new initiatives, the experiences shared by the panel experts are valuable for providing deeper insight into these new regulatory pathways and processes.
- Open Access
- 1 December 2021
- Published by Springer Nature in AAPS Open
- Vol. 7 (1) , 1-9
Meeting Report: Vaccine Stability Considerations to Enable Rapid Development and Deployment
The Stability Community of the American Association of Pharmaceutical Scientists (AAPS) held a virtual workshop on “Vaccine Stability Considerations to Enable Rapid Development and Deployment”, on March 24-25, 2021. The workshop included distinguished speakers and panelists from across the industry, academia, regulatory agencies, as well as health care leaders. This paper presents a review of the topics covered. Specifically the challenges in accelerating vaccine development and analytical characterization techniques to establish shelf-life were covered. Additionally, vaccine stability modeling using prior knowledge stability models and advanced kinetic analysis played a key in the EUA approaches discussed during the workshop. Finally, the role of stability studies in addressing the challenges of vaccine distribution and deployment during the pandemic were a focus of presentations and panel discussions.Although the workshop did not have any presentation topics directly dedicated to the mRNA vaccines, the techniques discussed are generally applicable. The mRNA vaccine developers were represented in the panel discussions, where experts involved in the EUA approval/deployment stages for this vaccine type could discuss the challenges as applied to their vaccines.
- 1 December 2021
- Published by Springer Nature in AAPS Open
- Vol. 7 (1) , 1-9
Open AccessMeeting Report: Vaccine Stability Considerations to Enable Rapid Development and Deployment
The Stability Community of the American Association of Pharmaceutical Scientists (AAPS) held a virtual workshop on “Vaccine Stability Considerations to Enable Rapid Development and Deployment”, on March 24-25, 2021. The workshop included distinguished speakers and panelists from across the industry, academia, regulatory agencies, as well as health care leaders. This paper presents a review of the topics covered. Specifically the challenges in accelerating vaccine development and analytical characterization techniques to establish shelf-life were covered. Additionally, vaccine stability modeling using prior knowledge stability models and advanced kinetic analysis played a key in the EUA approaches discussed during the workshop. Finally, the role of stability studies in addressing the challenges of vaccine distribution and deployment during the pandemic were a focus of presentations and panel discussions.Although the workshop did not have any presentation topics directly dedicated to the mRNA vaccines, the techniques discussed are generally applicable. The mRNA vaccine developers were represented in the panel discussions, where experts involved in the EUA approval/deployment stages for this vaccine type could discuss the challenges as applied to their vaccines.
- Open Access
- 12 December 2018
- Published by Springer Nature in AAPS Open
- Vol. 4 (1) , 9
ANVISA: an introduction to a new regulatory agency with many challenges
- 12 December 2018
- Published by Springer Nature in AAPS Open
- Vol. 4 (1) , 9
Open AccessANVISA: an introduction to a new regulatory agency with many challenges
- 30 May 2015
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 16 (4) , 986-991
Strategies of Bringing Drug Product Marketing Applications to Meet Current Regulatory Standards
In the past decade, many guidance documents have been issued through collaboration of global organizations and regulatory authorities. Most of these are applicable to new products, but there is a risk that currently marketed products will not meet the new compliance standards during audits and inspections while companies continue to make changes through the product life cycle for continuous improvement or market demands. This discussion presents different strategies to bringing drug product marketing applications to meet current and emerging standards. It also discusses stability and method designs to meet process validation and global development efforts.
- 30 May 2015
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 16 (4) , 986-991
Strategies of Bringing Drug Product Marketing Applications to Meet Current Regulatory Standards
In the past decade, many guidance documents have been issued through collaboration of global organizations and regulatory authorities. Most of these are applicable to new products, but there is a risk that currently marketed products will not meet the new compliance standards during audits and inspections while companies continue to make changes through the product life cycle for continuous improvement or market demands. This discussion presents different strategies to bringing drug product marketing applications to meet current and emerging standards. It also discusses stability and method designs to meet process validation and global development efforts.
- 20 October 2009
- Published by Springer Nature
- p. 61-66
Regulatory Requirements for Stability Testing of Generics
- 20 October 2009
- Published by Springer Nature
- p. 61-66
Regulatory Requirements for Stability Testing of Generics
- 20 October 2009
- Published by Springer Nature
- p. 45-50
Requirements for South East Asian Markets
- 20 October 2009
- Published by Springer Nature
- p. 29-35
Development of a Regional Guideline for the Eastern Mediterranean Region
- 20 October 2009
- Published by Springer Nature
- p. 29-35
Development of a Regional Guideline for the Eastern Mediterranean Region
- 20 October 2009
- Published by Springer Nature
- p. 229-237
Highlights of Investigating Out-of-Specifications Test Results
- 20 October 2009
- Published by Springer Nature
- p. 229-237
Highlights of Investigating Out-of-Specifications Test Results
- 20 October 2009
- Published by Springer Nature
- p. 9-13
Regulatory Perspectives on Product Stability